BB Biotech AG increased its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 1.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,869,528 shares of the biopharmaceutical company’s stock after buying an additional 30,000 shares during the quarter. Agios Pharmaceuticals accounts for approximately 4.5% of BB Biotech AG’s investment portfolio, making the stock its 9th largest position. BB Biotech AG owned approximately 5.95% of Agios Pharmaceuticals worth $147,637,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the company. State Board of Administration of Florida Retirement System increased its stake in shares of Agios Pharmaceuticals by 0.3% in the first quarter. State Board of Administration of Florida Retirement System now owns 39,473 shares of the biopharmaceutical company’s stock valued at $2,305,000 after buying an additional 126 shares during the period. Bank of Montreal Can increased its stake in shares of Agios Pharmaceuticals by 11.7% in the first quarter. Bank of Montreal Can now owns 2,068 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 216 shares during the period. Creative Planning increased its stake in shares of Agios Pharmaceuticals by 1.4% in the second quarter. Creative Planning now owns 16,710 shares of the biopharmaceutical company’s stock valued at $860,000 after buying an additional 228 shares during the period. Public Employees Retirement Association of Colorado increased its stake in shares of Agios Pharmaceuticals by 5.2% in the second quarter. Public Employees Retirement Association of Colorado now owns 6,504 shares of the biopharmaceutical company’s stock valued at $335,000 after buying an additional 323 shares during the period. Finally, BNP Paribas Arbitrage SA increased its stake in shares of Agios Pharmaceuticals by 2.9% in the second quarter. BNP Paribas Arbitrage SA now owns 13,575 shares of the biopharmaceutical company’s stock valued at $698,000 after buying an additional 385 shares during the period. 94.40% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “BB Biotech AG Has $147.64 Million Stake in Agios Pharmaceuticals, Inc. (AGIO)” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/09/22/bb-biotech-ag-has-147-64-million-stake-in-agios-pharmaceuticals-inc-agio.html.

Agios Pharmaceuticals, Inc. (NASDAQ AGIO) traded down 1.10% during mid-day trading on Friday, reaching $66.38. 45,921 shares of the company’s stock were exchanged. The stock’s market cap is $3.21 billion. The stock has a 50-day moving average of $60.83 and a 200-day moving average of $54.73. Agios Pharmaceuticals, Inc. has a one year low of $39.24 and a one year high of $67.74.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.57) by ($0.21). Agios Pharmaceuticals had a negative net margin of 502.12% and a negative return on equity of 68.15%. The company had revenue of $11.30 million during the quarter, compared to the consensus estimate of $10.68 million. During the same quarter in the previous year, the firm posted ($1.47) EPS. The business’s revenue for the quarter was up 62.1% compared to the same quarter last year. On average, equities research analysts anticipate that Agios Pharmaceuticals, Inc. will post ($7.07) earnings per share for the current year.

Several research firms have recently issued reports on AGIO. BidaskClub downgraded Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. SunTrust Banks, Inc. reaffirmed a “buy” rating and issued a $80.00 price objective (up previously from $68.00) on shares of Agios Pharmaceuticals in a research note on Tuesday, August 8th. Needham & Company LLC upped their price objective on Agios Pharmaceuticals from $54.00 to $72.00 and gave the company a “buy” rating in a research note on Thursday, August 10th. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and issued a $83.00 price objective (up previously from $75.00) on shares of Agios Pharmaceuticals in a research note on Thursday, August 10th. Finally, J P Morgan Chase & Co reaffirmed a “buy” rating and issued a $76.00 price objective on shares of Agios Pharmaceuticals in a research note on Monday. Four research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $75.20.

In other news, CEO David P. Schenkein sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $51.18, for a total transaction of $153,540.00. Following the transaction, the chief executive officer now directly owns 3,000 shares of the company’s stock, valued at $153,540. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Lewis Clayton Jr. Cantley sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 13th. The shares were sold at an average price of $65.47, for a total value of $65,470.00. Following the transaction, the director now directly owns 86,394 shares in the company, valued at $5,656,215.18. The disclosure for this sale can be found here. Insiders sold 134,938 shares of company stock valued at $8,359,112 in the last quarter. Corporate insiders own 10.55% of the company’s stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO).

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.